目的：研究复方苦参注射液应用于原发性肝癌晚期治疗中的临床疗效及对患者相关炎症指标、肿瘤标志物表达水平的影响。方法：选取本院2015年1月～2017年6月间收治的92例原发性肝癌晚期患者作为入组资料，分组方法：按随机数字表法将入选患者均分为对照组与观察组，对照组采取吉西他滨联合奥沙利铂化疗，观察组在对照组的基础上应用复方苦参注射液治疗，两组均治疗2个化疗周期共计42d；治疗两个化疗周期后，评估两组临床疗效，观察两组患者治疗前后血清指标表达水平的变化情况；随访一年，评估两组患者生活质量，统计两组患者的无病情进展生活时间（PFS）与总生存时间（OS）并进行生存函数分析。结果：观察组局部控制率为91.30%，对照组局部控制率为63.04%，观察组局部控制率与整体疗效水平均优于对照组（P<0.05）；治疗后观察组IFN-γ水平高于对照组，TNF-α、CEA、VEGF水平低于对照组（P<0.05）；治疗后两组患者生理、心理、社会关系、环境各维度评分均增高（P<0.05），且观察组均高于对照组（P<0.05）；观察组PFS、OS均长于对照组（P<0.05）。结论：复方苦参注射液能够提高原发性肝癌晚期患者的临床疗效，改善炎症指标及肿瘤标志物的表达水平，提高患者的生活质量，并可延长患者PFS及OS。 关键词：原发性肝癌；生活质量；复方苦参注射液；血清指标

ervation group was treated with compound radix sophora flavescens injection on the basis of treatment in the control group, and both groups were treated with 2 cycles of chemotherapy for a total of 42d. After the treatment of two chemotherapy cycles, the clinical efficacy of the two groups was evaluated, followed by the observation of changes in serum tumor marker expressions before and after the treatment of the two groups. Furthermore, patients were followed up for one year to evaluate the quality of life of the two groups, and the progression-free-survival (PFS) and overall survival time (OS) of the two groups were statistically analyzed, with survival function analysis at the same time. Results: The local control rate of the observation group was 82.35%, and that of the control group was 56.86%. The local control rate and overall curative effect of the observation group were both better than those of the control group (P<0.05). After treatment, the IFN-γ level of the observation group was higher than that of the control group after treatment, and the levels of TNF-α, CEA, and VEGF were lower than those of the control group (P<0.05). After treatment, the scores of the physical, psychological, social relations, and environmental dimensions increased in both groups of patients (P<0.05), and the observation group was higher than that in the control group (P<0.05). In addition, the PFS and OS of the observation group were longer than those in the control group (P <0.05). Conclusion: Compound Sophora flavscens injection can improve the clinical efficacy of patients with advanced primary hepatocellular carcinoma, elevate the expression of inflammatory indicators and tumor markers, improve the quality of life of patients, and prolong PFS and OS.